Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study.

48 , 49 In a recent interventional, open-label, real-world Canadian study undertaken to examine the association between patient-reported cognitive symptoms and workplace productivity in working patients with MDD treated with vortioxetine (Assessment in Work productivity and the Relationship with Cognitive symptoms [AtWoRC] study), a highly significant positive correlation was seen between improvements in cognitive symptoms and improvements in functioning and workplace productivity after 12 and 52 weeks of vortioxetine treatment. 50 , 51 As in the present study, SEM analyses confirmed that improvements in cognitive symptoms predicted long-term improvements in functional outcomes even after adjusting for severity of depressive symptoms. 51 A major strength of this study is that it was performed in a real-world setting with long-term longitudinal follow-up of a large cohort of patients, most of whom were enrolled and followed up by GPs.

also in 132,142 other papers